Skip to main content

Suppression of programmed cell death in industrial scale biological production systems

Objective

Apoptosis is the genetically determined form of controlled cellular elimination that accounts for most of the cell death that takes place in-vivo. It is also the primary mechanism of cell death during the in-vitro cultivation of mammalian cell lines used in the production of biopharmaceuticals. In recent years, lab scale studies have indicated that the suppression of the apoptotic pathway during the synthesis of these high value products can substantially increase the productivity of the culture process. In the demonstration proposed here, we will develop new cell lines that incorporate anti-apoptosis genes and will demonstrate the impact of this strategy on the efficiency of state of the art industrial-scale biopharmaceucical production processes, and then make them available to the biotechnology industry.
- Assessment of transfectants over-expressing Bcl-2 protein, generated in previous programme, in a state-of-the-art biopharmaceutical manufacturing process was completed;
- Bank of NS0 clones expressing different levels of Bcl-2 protein secured and selected clones characterised.

Funding Scheme

DEM - Demonstration contracts

Coordinator

UNIVERSITY OF BIRMINGHAM
Address
Edgbaston
B15 2TT Birmingham
United Kingdom

Participants (2)

LONZA BIOLOGICS PLC
United Kingdom
Address
228 Bath Road
SL1 4DI Slough
TUHH-TECHNOLOGIE GMBH
Germany
Address
Denickerstrasse 15
21073 Hamburg